These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
281 related articles for article (PubMed ID: 26036311)
1. Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer. Zucha MA; Wu AT; Lee WH; Wang LS; Lin WW; Yuan CC; Yeh CT Oncotarget; 2015 May; 6(15):13255-68. PubMed ID: 26036311 [TBL] [Abstract][Full Text] [Related]
2. Preclinical investigation of ibrutinib, a Bruton's kinase tyrosine (Btk) inhibitor, in suppressing glioma tumorigenesis and stem cell phenotypes. Wei L; Su YK; Lin CM; Chao TY; Huang SP; Huynh TT; Jan HJ; Whang-Peng J; Chiou JF; Wu AT; Hsiao M Oncotarget; 2016 Oct; 7(43):69961-69975. PubMed ID: 27564106 [TBL] [Abstract][Full Text] [Related]
3. Inhibiting Bruton's Tyrosine Kinase to Counteract Chemoresistance and Stem Cell-Like Properties in Osteosarcoma. Tsai HC; Lien MY; Wang SW; Fong YC; Tang CH Environ Toxicol; 2024 Nov; 39(11):4936-4945. PubMed ID: 38924303 [TBL] [Abstract][Full Text] [Related]
4. Activity of Bruton's tyrosine-kinase inhibitor ibrutinib in patients with CD117-positive acute myeloid leukaemia: a mechanistic study using patient-derived blast cells. Rushworth SA; Pillinger G; Abdul-Aziz A; Piddock R; Shafat MS; Murray MY; Zaitseva L; Lawes MJ; MacEwan DJ; Bowles KM Lancet Haematol; 2015 May; 2(5):e204-11. PubMed ID: 26688095 [TBL] [Abstract][Full Text] [Related]
5. Ibrutinib (PCI-32765), the first BTK (Bruton's tyrosine kinase) inhibitor in clinical trials. Brown JR Curr Hematol Malig Rep; 2013 Mar; 8(1):1-6. PubMed ID: 23296407 [TBL] [Abstract][Full Text] [Related]
6. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies. Aw A; Brown JR Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906 [TBL] [Abstract][Full Text] [Related]
7. Bruton's tyrosine kinase (BTK) as a promising target in solid tumors. Molina-Cerrillo J; Alonso-Gordoa T; Gajate P; Grande E Cancer Treat Rev; 2017 Jul; 58():41-50. PubMed ID: 28641100 [TBL] [Abstract][Full Text] [Related]
8. Ibrutinib treatment of CLL: the cancer fights back. Young RM; Staudt LM Cancer Cell; 2014 Jul; 26(1):11-3. PubMed ID: 25026208 [TBL] [Abstract][Full Text] [Related]
10. Bortezomib enhances the anti-cancer effect of the novel Bruton's tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK. Wang X; Fei Y; Liu X; Zhang T; Li W; Jia X; Liu X; Qiu L; Qian Z; Zhou S; Ren X; Zhai Q; Meng B; Li L; Zhang H Aging (Albany NY); 2021 Sep; 13(17):21102-21121. PubMed ID: 34508613 [TBL] [Abstract][Full Text] [Related]
11. Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies. Wang Y; Zhang LL; Champlin RE; Wang ML Clin Pharmacol Ther; 2015 May; 97(5):455-68. PubMed ID: 25669675 [TBL] [Abstract][Full Text] [Related]
12. Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells. Wang X; Wong J; Sevinsky CJ; Kokabee L; Khan F; Sun Y; Conklin DS Mol Cancer Ther; 2016 Sep; 15(9):2198-208. PubMed ID: 27256378 [TBL] [Abstract][Full Text] [Related]
13. The Bruton's tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages. Ping L; Ding N; Shi Y; Feng L; Li J; Liu Y; Lin Y; Shi C; Wang X; Pan Z; Song Y; Zhu J Oncotarget; 2017 Jun; 8(24):39218-39229. PubMed ID: 28424405 [TBL] [Abstract][Full Text] [Related]
14. Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment. Stiff A; Trikha P; Wesolowski R; Kendra K; Hsu V; Uppati S; McMichael E; Duggan M; Campbell A; Keller K; Landi I; Zhong Y; Dubovsky J; Howard JH; Yu L; Harrington B; Old M; Reiff S; Mace T; Tridandapani S; Muthusamy N; Caligiuri MA; Byrd JC; Carson WE Cancer Res; 2016 Apr; 76(8):2125-36. PubMed ID: 26880800 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of Bruton's Tyrosine Kinase Suppresses Cancer Stemness and Promotes Carboplatin-induced Cytotoxicity Against Bladder Cancer Cells. Pan Y; Chiu YH; Chiu SC; Cho DY; Lee LM; Wen YC; Whang-Peng J; Hsiao CH; Shih PH Anticancer Res; 2020 Nov; 40(11):6093-6099. PubMed ID: 33109547 [TBL] [Abstract][Full Text] [Related]
16. PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors. Yahiaoui A; Meadows SA; Sorensen RA; Cui ZH; Keegan KS; Brockett R; Chen G; Quéva C; Li L; Tannheimer SL PLoS One; 2017; 12(2):e0171221. PubMed ID: 28178345 [TBL] [Abstract][Full Text] [Related]
17. Strategies to overcome resistance mutations of Bruton's tyrosine kinase inhibitor ibrutinib. Liu L; Shi B; Wang X; Xiang H Future Med Chem; 2018 Feb; 10(3):343-356. PubMed ID: 29347836 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden. Abubaker K; Luwor RB; Zhu H; McNally O; Quinn MA; Burns CJ; Thompson EW; Findlay JK; Ahmed N BMC Cancer; 2014 May; 14():317. PubMed ID: 24886434 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]